Photoswitchable Inhibitor of the Calcium Channel TRPV6 was written by Cunha, Micael R.;Bhardwaj, Rajesh;Lindinger, Sonja;Butorac, Carmen;Romanin, Christoph;Hediger, Matthias A.;Reymond, Jean-Louis. And the article was included in ACS Medicinal Chemistry Letters in 2019.Reference of 182618-86-6 This article mentions the following:
Herein the authors report the first photoswitchable inhibitor of Transient Receptor Potential Vanilloid 6 (TRPV6), a selective calcium channel involved in a number of diseases and in cancer progression. By surveying analogs of a previously reported TRPV6 inhibitor appended with a phenyl-diazo group, the authors identified a compound switching between a weak TRPV6 inhibitor in its dark, E-diazo stereoisomer (Z/E = 3:97, IC50 >> 10 μM) and a potent inhibitor as the Z-diazo stereoisomer accessible reversibly by UV irradiation at λ = 365 nm (Z/E = 3:1, IC50 = 1.7±0.4 μM), thereby allowing precise spatiotemporal control of inhibition. This new tool compound should be useful to deepen the understanding of TRPV6. In the experiment, the researchers used many compounds, for example, 1-Boc-4-(4-Nitrophenyl)piperazine (cas: 182618-86-6Reference of 182618-86-6).
1-Boc-4-(4-Nitrophenyl)piperazine (cas: 182618-86-6) belongs to piperazine derivatives. Piperazine causes primary dermal irritation and skin burns at high concentrations. Piperazine also causes eye irritation in humans. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successful. Reference of 182618-86-6
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics